Lee Hung's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q3 2024
Question
Lee Hung asked about Crinetics' strategy for selecting candidates in the obesity space for 2025 and what criteria its GLP-1 or GIP programs must meet to advance in a highly competitive landscape.
Answer
CEO R. Struthers stated that the company is aiming for a 'best-in-class profile' and will not settle for less than a molecule they believe is near 'perfection.' Key criteria include superior manufacturability and tolerability, leveraging the advantages of small molecules over peptides to achieve an optimal clinical profile.